| 13.1 0.95 (7.82%) | 04-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.74 | 1-year : | 16.94 |
| Resists | First : | 13.47 | Second : | 14.51 |
| Pivot price | 13.05  |
|||
| Supports | First : | 11.81 | Second : | 9.82 |
| MAs | MA(5) : | 12.42 |
MA(20) : | 13.26 |
| MA(100) : | 14.01 |
MA(250) : | 14.49 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 22.5 |
D(3) : | 12.8 |
| RSI | RSI(14): 50.3 |
|||
| 52-week | High : | 18.44 | Low : | 10.61 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TRDA ] has closed below upper band by 48.1%. Bollinger Bands are 22.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.15 - 13.22 | 13.22 - 13.27 |
| Low: | 12.05 - 12.12 | 12.12 - 12.19 |
| Close: | 12.98 - 13.1 | 13.1 - 13.21 |
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Fri, 19 Apr 2024
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Is About To Turn The Corner - Yahoo Canada Shine On
Mon, 08 Apr 2024
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Movies UK
Thu, 28 Mar 2024
Insider Spends US$123k Buying More Shares In Entrada Therapeutics - Simply Wall St
Tue, 26 Mar 2024
Insider Buying: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Buys 3,180 Shares of Stock - MarketBeat
Tue, 19 Mar 2024
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates - Yahoo Finance
Fri, 15 Mar 2024
Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 34 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 15.4 (%) |
| Held by Institutions | 78.7 (%) |
| Shares Short | 1,770 (K) |
| Shares Short P.Month | 1,810 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.53 |
| Profit Margin | -5.2 % |
| Operating Margin | 11.7 % |
| Return on Assets (ttm) | -0.6 % |
| Return on Equity (ttm) | -3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.83 |
| EBITDA (p.s.) | -0.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 140 (M) |
| Levered Free Cash Flow | 149 (M) |
| PE Ratio | -65.5 |
| PEG Ratio | 0 |
| Price to Book value | 1.73 |
| Price to Sales | 3.41 |
| Price to Cash Flow | 3.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|